What is OnCusp?
OnCusp Therapeutics operates as a global biopharmaceutical enterprise dedicated to the rigorous translation of high-potential oncology assets. By bridging the gap between early-stage research and clinical application, the company maintains a specialized focus on first-in-class medicines. The organization is steered by a leadership team possessing extensive expertise in business development, clinical trial management, and the strategic scaling of life science ventures. Positioned at the intersection of innovation and commercialization, OnCusp is effectively navigating the competitive landscape of modern oncology, leveraging a robust portfolio to address significant unmet medical needs.
The company's growth trajectory is defined by a disciplined approach to asset selection and a commitment to operational excellence. By maintaining a lean, high-impact organizational structure, OnCusp ensures that its research initiatives remain agile while benefiting from the deep industry connections of its founding members. This strategic positioning allows the firm to attract top-tier institutional backing, facilitating the transition from laboratory-based discovery to advanced clinical development phases.
How much funding has OnCusp raised?
OnCusp has raised a total of $125M across 2 funding rounds:
Angel/Seed
$25M
Series A
$100M
Angel/Seed (2021): $25M with participation from Sequoia Capital, BioTrack Capital, AIHC Capital, and Oriza Seed Fund
Series A (2024): $100M led by BioTrack Capital, Catalio Capital Management, F-Prime Capital Partners, Marshall Wace, OrbiMed, and Novo Holdings
Key Investors in OnCusp
BioTrack Capital
A dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China, with a specific interest in biotech and medtech.
Catalio Capital Management
A New York-based investment firm specializing in innovative healthcare across private and public markets, focusing on breakthrough biomedical technology.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with deep therapeutic expertise.
What's next for OnCusp?
Following this major strategic investment, OnCusp Therapeutics is poised to enter a critical phase of clinical expansion. The capital will likely be deployed to advance its lead oncology candidates through rigorous regulatory milestones and expanded clinical trials. As the company matures, the focus will shift toward optimizing its development pipeline and potentially exploring strategic partnerships to enhance its market reach. The involvement of sophisticated healthcare investors suggests a long-term commitment to building a category-defining biopharmaceutical entity capable of delivering transformative outcomes in cancer treatment.
See full OnCusp company page
